Consumer perception, knowledge, and uses of cannabidiol

Author:

Nguyen CambreyORCID,Moeller Karen E.1ORCID,McGuire Michael2ORCID,Melton Brittany L.3ORCID

Affiliation:

1. 2 Clinical Professor, University of Kansas School of Pharmacy, Lawrence, Kansas

2. 3 Associate Professor, Belmont University College of Pharmacy, Nashville, Tennessee

3. 4 Associate Professor, University of Kansas School of Pharmacy, Lawrence, Kansas

Abstract

Abstract Introduction The legalization of cannabidiol (CBD) across the United States, in varying degrees, has made CBD easily accessible to consumers for complementary and medical purposes. However, there is a paucity of scientific evidence on the benefits and risks of commercially available CBD. In the literature, 2 studies have gathered consumer perceptions and attitudes on cannabis products, specifically CBD, using survey-based questionnaires. This study aimed to build on the aforementioned studies in obtaining consumer perception and knowledge of CBD products using a national survey-based questionnaire. Methods Respondents were recruited through an anonymous, nationwide, online survey administered through Qualtrics in the United States from March 28 to April 30, 2021. The survey consisted of demographics, perceived efficacy and safety of CBD, and resources to obtain CBD information. The survey responses were reported using descriptive statistics along with median and interquartile range for the Likert portion. Results A total of 1158 respondents accessed the survey. The median age was 43 and 50% of respondents were female. The uses for CBD included neurological disorders, pulmonary conditions, gastrointestinal disorders, and chronic pain. The most commonly reported safety concern related to taking CBD was anxiety. Participants agreed that CBD is safe when used responsibly for medical use, and social media was the main source used to obtain information about CBD. Discussion Respondents who used CBD for a condition thought it was helpful; however, most of the adverse effects were rated as moderate to severe, requiring medical attention from a health care professional, hospital, or emergency room visit.

Publisher

College of Psychiatric and Neurologic Pharmacists (CPNP)

Subject

Pharmacology (medical),Neurology (clinical),General Pharmacology, Toxicology and Pharmaceutics,Neuropsychology and Physiological Psychology

Reference32 articles.

1. Marijuana legalization: Impact on physicians and public health;Wilkinson;Annu Rev. Med,2016

2. Trends in internet searches for cannabidiol (CBD) in the United States;Leas;Jama Netw Open,2019

3. A scoping review of the use of cannabidiol in psychiatric disorders;Kirkland;Psychiatry Res,2022

4. Cannabidiol (CBD) consumption and perceived impact on extrahepatic symptoms in patients with autoimmune hepatitis;Mathur;Dig Dis Sci,2020

5. FDA regulation of cannabis and cannabis-derived products, including cannabidiol (CBD) [Internet];US Food and Drug Administration Office of the Commissioner,2020

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3